Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
some sort of heart issues that landed the patient in the hospital; This serious case was reported by a other health professional via sales rep and described the occurrence of heart disorder in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received the 1st dose of Arexvy (unknown deltoid). On an unknown date, an unknown time after receiving Arexvy, the patient experienced heart disorder (Verbatim: some sort of heart issues that landed the patient in the hospital) (serious criteria hospitalization and other: Serious per reporter). The outcome of the heart disorder was unknown. It was unknown if the reporter considered the heart disorder to be related to Arexvy. The company considered the heart disorder to be unrelated to Arexvy. Additional Information: GSK Receipt Date: 11-MAR-2026 The batch number was not provided and a request for this information had been made.; Sender's Comments: A case of Cardiac disorder, unknown time after receiving 1st dose of Arexvy, in a patient. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Further follow up information has been sought.